The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
2014 GA Agenda item 9.8 Falsified Medicines Directive
Related to GA 2014 Agenda item 9.8.
Since the last GA….
The General Assembly provides an opportunity to review the progress being made towards the implementation of the 2011 Falsified Medicines Directive across, and its potential impacts for the practice of hospital pharmacy.
The Directive requires that by 2017 all medicines in Europe be packaged with a safety feature to enable an assurance to take place of their veracity as a genuine product.
In practice, this will be implemented by means of a 2D bar code on the outer package that can be scanned 'at the point of dispensing'.
How this will be applied in the hospital sector, where the 'point of dispensing' is far less clear than in a community pharmacy (i.e. 'when the medicine is handed over to the patient'), remains the subject of discussion (when the medicine arrives at the hospital pharmacy? When it leaves the hospital pharmacy? When its administered to the patient?).
It is currently foreseen that there will be alot of scope for individual member states to interpret the requirements according to their own national system needs.
Two principal systems are in development to make implementation a reality:
- The European Stakeholder Model, which is a collaboration of PGEU (community pharmacists), EFPIA (originator industry), EAEPC (parallel trade) and GIRP (wholesalers); and,
- EDQM's E-tact system
The Policy Advocacy Officer will present some top line issues for member information and feedback.
Further information
Useful short summary here.
Further documents of a background nature may be added to this page in the weeks proceeding the General Assembly.